期刊
DIABETES OBESITY & METABOLISM
卷 16, 期 7, 页码 613-621出版社
WILEY
DOI: 10.1111/dom.12258
关键词
alogliptin; coadministration; combination therapy; dipeptidyl peptidase-4 inhibitor; DPP-4; metformin; monotherapy; T2DM; type 2 diabetes mellitus
资金
- Takeda Development Center Americas, Inc., Deerfield, IL, USA
- Takeda Development Centre Europe Ltd., London, UK
Aim: To evaluate the efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin plus metformin (A+M) initial combination therapy versus either as monotherapy in drug-naive T2DM patients. Methods: This international, randomized, double-blind, placebo-controlled, 26-week study involved T2DM patients with hyperglycaemia (HbA1c 7.5-10.0%) following diet/exercise therapy. Patients (N=784) received placebo, alogliptin (A, 12.5 mg BID or 25 mg QD), metformin (M, 500 or 1000 mg BID) or A+M (12.5/500 or 12.5/1000 mg BID); placebo, A25 for secondary analyses only. Endpoints: week 26 changes from baseline in HbA1c (primary), fasting plasma glucose (FPG) and 2-h postprandial glucose (PPG); incidences of clinical response and hyperglycaemic rescue. Results: Week 26 mean HbA1c reductions from baseline (8.45%) were -1.22 and -1.55% with A+M 12.5/500 and 12.5/1000 versus -0.56, -0.65, and -1.11% with A12.5, M500 and M1000 (p<0.001, A+M vs. component monotherapies). FPG reductions were -1.76 and -2.55 mmol/L with 12.5/500 and 12.5/1000 versus -0.54, -0.64 and -1.78 mmol/L with A12.5, M500 and M1000 (p<0.05, A+M vs. component monotherapies). Significantly more A+M-treated patients achieved HbA1c<7% (47.1-59.5% vs. 20.2-34.3% with monotherapy), significantly fewer required hyperglycaemic rescue (2.6-12.3% vs. 10.8-22.9% with monotherapy). A+M caused only mild/moderate hypoglycaemia (1.9-5.3%) and weight loss (0.6-1.2 kg). Conclusions: Alogliptin plus metformin initial combination therapy was well tolerated yet more efficacious in controlling glycaemia in drug-naive T2DM patients than either as monotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据